An interventional study of Multidomain Intervention Targeting Cognitive Decline in Diabetes, Diabetes Mellitus Type 2 and Type 2 Diabetes, sponsored by Steno Diabetes Center Copenhagen. Recruiting at 3 sites in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Steno Diabetes Center Copenhagen · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen — 8 open to participants now, 10 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Steno Diabetes Center Copenhagen.
Among the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, this one has the largest planned enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2024, is one of 17 with no phase, and was the 26th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →8 of the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen are open now, in 2 countries. Recruiting first, the newest first:
Steno Diabetes Center Copenhagen · Sites in Denmark
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18+
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18–74
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 18+
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 50–75 · Healthy volunteers
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 420 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 94 across the 24 interventional studies, 148 across the 6 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Steno Diabetes Center Copenhagen is the lead sponsor of 114 studies on the registry; 22 are open to participants now.
3 of the studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07262788Steno Diabetes Center CopenhagenA Feasibility Study of Optimal Non-Pharmacological Lifestyle Modifications in People With Type 2 Diabetes | 2027-03 |
| NCT07645079Steno Diabetes Center CopenhagenAutomated Insulin Delivery Versus Daily Injections for Hospital Diabetes Care | 2027-07-15 |
| NCT07641309Steno Diabetes Center CopenhagenMeasurements Before and After Participation in a Health Intervention Programme in Halsnaes Municipality | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 31 studies in Diabetes Mellitus, Type 2 by Steno Diabetes Center Copenhagen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of The Brain Care Study is to investigate the prevalence of cognitive impairment in older adults with type 2 diabetes (T2D) and to evaluate the effectiveness of a multidomain intervention designed to prevent cognitive decline.
Type 2 diabetes (T2D) is a chronic condition associated with cognitive decline and an increased risk of Alzheimer's disease and vascular dementia. Cognitive impairment in individuals with T2D complicates disease management, often leading to poorer clinical outcomes. Although guidelines recommend cognitive screening for older adults with T2D, uncertainties remain regarding how to best identify high-risk individuals and adjust treatment strategies. While multidomain interventions have shown potential in delaying cognitive decline, further research is needed to develop feasible and effective strategies for at-risk populations.
The Brain Care Study consists of two parts: a prevalence study involving cognitive screening and a two-year randomized controlled trial (RCT) to assess a multidomain intervention targeting multiple risk factors, including pharmacological optimization, lifestyle changes, and social interaction.
The multidomain intervention focuses on optimizing medication, adjusting HbA1c targets, managing vascular risk factors, and addressing hearing impairment, depression, physical activity, and cognitive training. Additionally, the study will employ dialogue tools, text message reminders, and social interaction to enhance participants' health and adherence to the intervention.
The study hypothesizes that cognitive screening will be feasible and will not increase diabetes-related distress, while the intervention may reduce cognitive decline, improve health-related quality of life, decrease hospitalization rates, and minimize the need for home visits or relocation to nursing homes. Study endpoints include the prevalence of cognitive impairment, changes in cognitive function, hospitalization rates, and medication adherence, with the goal of providing evidence-based recommendations for future diabetes care guidelines.
Overall, the Brain Care Study aims to quantify the prevalence of cognitive decline in older individuals with type 2 diabetes and generate data to inform future guidelines for cognitive screening and interventions in this population.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
This study's planned enrollment of 420 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Steno Diabetes Center Copenhagen is the lead sponsor of 114 studies on the registry; 22 are open to participants now.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria for the Prevalence Study (Cognitive Screening):
Inclusion Criteria for the Randomized Controlled Trial (Multidomain Intervention):
Meets all the above inclusion criteria, and at least one of the following:
At least 2 out of 5 SCIP subtests with a score ≥ 1 SD below the age- and education-adjusted norm
Exclusion Criteria for the Prevalence Study (Cognitive Screening):
Exclusion Criteria for the Randomized Controlled Trial (Multidomain Intervention):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Multidomain Intervention Targeting Cognitive Decline
The multidomain intervention will include the following: Optimization of pharmacological treatment/Pharmacological neuroprotection. Adjustment of HbA1c targets. Vascular risk factor management. Assessment of hearing impairment. Assessment of depression. Dialogue tools. Social interaction. Guidance on physical training. Cognitive training. Text message reminders.
Difference in Change in Cognitive Function
Difference in change in cognitive function (visit 1 compared to follow-up) measured by SCIP between the multifactorial intervention group and the usual care group.
Time frame: 2 years
The Number of Hospitalizations Related to All-cause Disease
Time frame: 2 years
Changes in Health-related Quality of Life Measured by SF-36
Time frame: 2 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Jun 2029, 60 months after the start.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 60 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Steno Diabetes Center Copenhagen →